Intrathecal chemotherapy and meningeal relapses in myelomonocytic AML. A single institution experience.
Romani
Claudio
C
Di Tucci
Anna Angela
AA
Dessalvi
Paolo
P
Pettinau
Martina
M
Emanuele
Angelucci
A
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007278:Injections, Spinal; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy* / Q000473:pathology; D017254:Leukemic Infiltration / Q000188:drug therapy / Q000517:prevention & control*; D008297:Male; D008578:Meninges / Q000473:pathology*; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D013737:Testis / Q000473:pathology; D055815:Young Adult
D003561:Cytarabine; D005047:Etoposide; D008942:Mitoxantrone; D015255:Idarubicin; D003630:Daunorubicin